<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023161</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2021/12</org_study_id>
    <nct_id>NCT05023161</nct_id>
  </id_info>
  <brief_title>Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction</brief_title>
  <acronym>DPNI-RCIU</acronym>
  <official_title>Non-invasive Prenatal Testing of Placental Chromosomal Abnormalities in Fetus With Intrauterine Growth Restriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project is the non-invasive prenatal detection of placenta-limited&#xD;
      aneuploidies, in patients whose fetuses have a intrauterine growth restriction below 3rd&#xD;
      percentile, in parallel with an amniocentesis.&#xD;
&#xD;
      This study will allow the chromosomal study of the placenta in pregnant women whose genetic&#xD;
      prenatal diagnosis, made by amniocentesis, does not allow exploring the placental causes of&#xD;
      fetal RCIU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Placental chromosomal aneuploidies will be detected by high-throughput whole genome&#xD;
      sequencing of non-cellular DNA present in maternal plasma during pregnancy.&#xD;
&#xD;
      The study of the cfDNA will be carried out from a blood sample with the automated solution&#xD;
      VERISEQ NIPT (Illumina) using the software illumina VeriSeq v2, allowing the detection of all&#xD;
      chromosomal abnormalities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the presence or absence of chromosomal abnormality in the plasma sample. studied.</measure>
    <time_frame>Inclusion date</time_frame>
    <description>The result will be expressed in presence or absence of chromosomal abnormality such as trisomy, monosomy, deletion or duplication. The result will be compared with the fetal chromosome analysis carried out concomitantly on liquid amniotic as part of the treatment: if the analysis on Liquid Amniotic shows the same anomaly, it means that it is a fetal abnormality, if the Liquid Amniotic test is normal, it means that it is most likely an abnormality placental chromosome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the proportion of chromosomal placental etiology in Intrauterine Growth Restriction.</measure>
    <time_frame>Inclusion date</time_frame>
    <description>Proportion will be described in terms of percentage counts and 95% confidence interval depending on the test Fisher's exact (p &lt;0.05)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fetal Growth Retardation</condition>
  <arm_group>
    <arm_group_label>Patient having a fetus with intra-uterine growth restriction diagnosis below the 3rd percentile</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Performed a 10 ml blood sample in each of the 200 patients included.</description>
    <arm_group_label>Patient having a fetus with intra-uterine growth restriction diagnosis below the 3rd percentile</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient having a fetus with IUGR diagnosis below the 3rd percentile (after reference&#xD;
        medical ultrasound)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  over 18 years old,&#xD;
&#xD;
          -  treated in the DDIANE fetal medicine centre at the Bordeaux University Hospital,&#xD;
&#xD;
          -  having a fetus with IUGR diagnosis below the 3rd percentile (after reference medical&#xD;
             ultrasound),&#xD;
&#xD;
          -  from 16 weeks of amenorrhea or more,&#xD;
&#xD;
          -  accepting an Invasive Prenatal Diagnosis by amniocentesis with array comparative&#xD;
             genomic hybridization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Childbearing women who:&#xD;
&#xD;
          -  do not accept a non-invasive prenatal diagnosis (amniocentesis)&#xD;
&#xD;
          -  have a fetus with non-isolated IUGR (associated with other ultrasound signs)&#xD;
&#xD;
          -  do not consent to participate in the research protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>having a fetus with IUGR diagnosis below the 3rd percentile (after reference medical ultrasound)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Caroline THAMBO</last_name>
    <phone>05 56 79 59 52</phone>
    <email>caroline.rooryck-thambo@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Virginie RACLET</last_name>
    <phone>05 56 79 59 52</phone>
    <email>virginie.raclet@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline THAMBO</last_name>
      <phone>05 56 79 59 52</phone>
      <email>caroline.rooryck-thambo@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Invasive Prenatal Testing</keyword>
  <keyword>cell- free DNA</keyword>
  <keyword>trisomy</keyword>
  <keyword>placenta confined mosaic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

